Oncotarget

Research Papers:

Correlation between serum IL-1β and miR-144-3p as well as their prognostic values in LUAD and LUSC patients

Chen Wu, Bin Xu, You Zhou, Mei Ji, Dachuan Zhang, Jingting Jiang and Changping Wu _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:85876-85887. https://doi.org/10.18632/oncotarget.13042

Metrics: PDF 2023 views  |   HTML 2137 views  |   ?  


Abstract

Chen Wu1,2,3, Bin Xu3,4, You Zhou3,4, Mei Ji1,3, Dachuan Zhang5, Jingting Jiang2,3,4, Changping Wu1,2,3

1Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, P.R.China

2Institute of Cell Therapy, Soochow University, Changzhou, 213003, P.R.China

3Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, 213003, P.R.China

4Department of Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, P.R.China

5Department of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, P.R.China

Correspondence to:

Jingting Jiang, email: [email protected]

Changping Wu, email: [email protected]

Keywords: LUAD, LUSC, IL-1β, miR-144-3p, prognosis

Received: September 06, 2016     Accepted: October 28, 2016     Published: November 03, 2016

ABSTRACT

Background: IL-1β is an essential factor of inflammation initiation, and it also promotes malignant transformation, indicating its tumorigenic property. We aimed to investigate the correlation between IL-1β and miR-144-3p as well as their prognostic values in LUAD and LUSC patients.

Results: The IL-1β level in both LUAD and LUSC patients was significantly higher than that of healthy donors (P < 0.001). In both populations, patients with low IL-1β level had better prognosis than high IL-1β level (P < 0.001 and P = 0.010, respectively). In A549 cells, miR-144 showed the biggest expression change (−4.38 fold) after IL-1β exposure. In LUAD patients, a negative correlation was detected between IL-1β and miR-144-3p (r = –0.540, P < 0.001) and the high miR-144-3p group had better prognosis (P = 0.003), which was validated by TCGA data. Clinical stage, IL-1β and miR-144-3p were independent risk factors in LUAD patients. In vitro, IL-1β and miR-144-3p antagomir could enhance proliferation and miR-144-3p mimics would attenuate the promoting effect of IL-1β.

Materials and Methods: ELISA and qRT-PCR were applied respectively to detected cytokines and miR-144-3p in 129 LUAD, 54 LUSC and 40 healthy donors. Moreover, miRNA array was carried out for miRNA profiling. TCGA database was employed for validation, and follow up data were collected for prognosis evaluation. MTT assay and western-blot were carried out for proliferation evaluation.

Conclusions: In LUAD patients, the serum IL-1β level was correlated with miR-144-3p may affect miR-144-3p at transcriptional level. Both of them were independent risk factors for LUAD prognosis. In addition, IL-1β and miR-144-3p might mediate inflammation-promoted tumorigenesis in LUAD patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13042